Meta Platforms, Inc. (META.US) poured USD900 million in Indian fintech startup Cred, acquiring an approximately 20% stake, with plans to appoint Cred founder Kunal Shah as the new head of WhatsApp.

Cred operates an App that rewards users for paying their credit card bills on time. Cred is currently valued at USD4.5 billion post-investment.

Shah will succeed current WhatsApp head Will Cathcart, who has led WhatsApp for about seven years. During his tenure, WhatsApp's user base more than doubled.

A Meta spokesperson declined to disclose details of Cathcart’s next project.
~

AASTOCKS Financial News
Website: www.aastocks.com

Attracting over 15.7 million MICE visits since 2007
Elevating Macao's international competitiveness through long-term
non-gaming investment

MACAO, June 22, 2026 /PRNewswire/ -- Since the opening of Sands^® Macao in 2004, Sands China Ltd. has remained committed to contributing to Macao's development into a World Centre of Tourism and Leisure. As a trailblazer of Macao's integrated resort model, Sands China has placed hospitality, retail, entertainment, and MICE (meetings, incentives, conferences and exhibitions) at the core of its non-gaming development strategy. For over two decades, the company has continuously invested in both infrastructure and software to broaden the scope and depth of the city's industries, in support of the Macao SAR government's economic diversification direction.

With the opening of The Venetian^® Macao in 2007, Sands China took a forward-looking approach by establishing Cotai Expo, the largest MICE facility in Macao — laying a solid foundation for the city's international competitiveness in the MICE industry. Over the years, the company has been steadfast in advancing non-gaming development, driving Macao's MICE sector to evolve from an emerging industry into a high-growth pillar. Sands China successfully developed and enriched the integrated model that enables multiple experiences within a single stop. To date, the company's total MICE facilities span over 1.6 million square feet, continuing to scale the international and professional development of the sector.

Under strong policy support from both the central and Macao SAR governments, Macao's MICE industry has expanded significantly, becoming one of the key engines driving progress in the city's diversification. Sands China has long played a proactive role in promoting the industry's advancement. It has leveraged its world-class integrated resorts to enhance Macao's capacity and competitiveness in hosting large-scale international MICE events, successfully attracting a wide range of globally influential, high-value conferences and exhibitions to the city.

As of now, Sands China has hosted nearly 12,800 MICE events across a broad spectrum of global industries, attracting over 15.7 million MICE visits from around the world. These efforts continue to strengthen Macao's position as one of the premier MICE tourism destinations in Greater China, Asia, and globally.

Sands China firmly believes that MICE serves as a powerful economic multiplier, conducive to fostering the development of related industries. Its strong international connectivity also enables the city to attract a broad base of global business travellers and professionals, further expanding Macao's international source markets. Sands China has long tapped into the continued hosting of high-quality international MICE events as part the company's approach to elevate Macao's appeal to global tourists. In 2025 alone, Sands China recorded 380,000 room nights by international guests across its integrated resorts.

Grant Chum, chief executive officer and executive director of Sands China Ltd., said: "Over the years, Sands China has played a pivotal role in developing Macao's MICE industry, integrating MICE deeply within our integrated resort model. We have built large-scale, high-quality MICE infrastructure in Macao, continuously elevating the sector into a strategic drawcard and tourism product that connects Macao with global markets, strengthens the city's international competitiveness, and supports its broader economic diversification. Since 2007, Sands China has attracted over 15.7 million MICE visits. As the local MICE industry continues to flourish, Macao has increasingly established itself as one of the world's most influential business and tourism destinations, underscoring the sector's contribution to the city's diversified economic growth.

"Looking ahead, Sands China will continue to align closely with the Macao SAR government's 'Tourism+' policy. Through the continued strengthening of synergies across non-gaming sectors, our company endeavours to further elevate Macao's global competitiveness and appeal, while supporting the development of its diversified economy, and remains committed to consolidating the city's position as a World Centre of Tourism and Leisure."

Sands China holds unwavering confidence in Macao's long term development trajectory. As the company continues to strengthen its business performance, it maintains its commitment to long-term investment in the city. The company is proactively deepening high-quality, non-gaming "Tourism+" initiatives to support Macao's overall development strategy –– striving to further enrich Macao's appeal as a City of Events and contribute to its long-term, sustainable and diversified growth.

About Sands China Ltd. 
Sands China Ltd. (Sands China or the Company) is incorporated in the Cayman Islands with limited liability and is listed on The Stock Exchange of Hong Kong Limited (HKEx: 1928). Sands China is the largest operator of integrated resorts in Macao. The Company's integrated resorts on the Cotai Strip comprise The Venetian^® Macao, The Plaza^® Macao, The Parisian^® Macao and The Londoner^® Macao. The Company also owns and operates Sands^® Macao on the Macao peninsula. The Company's portfolio features a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities; a wide range of restaurants; shopping malls; world-class entertainment at The Venetian Arena, The Londoner Arena, The Venetian Theatre, The Parisian Theatre, The Londoner Theatre and Sands Theatre; and a high-speed Cotai Water Jet ferry service between Hong Kong and Macao. The Company's Cotai Strip portfolio has the goal of contributing to Macao's transformation into a world centre of tourism and leisure. Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).

For more information, please visit www.sandschina.com.

Media contacts:
Corporate Communications, Sands China Ltd.
Mabel Wu
Tel: +853 8118 2268
Email: [email protected]

Jesse Chiang
Tel: +853 8118 2054
Email: [email protected]

自二零零七年至今吸引逾1,570萬人次參展
共建城市國際競爭力   彰顯持續非博彩投入 

澳門2026年6月22日 /美通社/ -- 自2004年澳門金沙開業至今，金沙中國一直與澳門並肩同行，致力為澳門發展成為世界旅遊休閒中心貢獻力量。作為澳門綜合度假村營運模式的先驅，公司以酒店、零售、娛樂及會展等非博彩業務板塊作為企業發展核心，二十多年來全力配合澳門特區政府經濟適度多元發展的施政方針，從不間斷投放軟硬件資源，驅動澳門產業多元發展。

金沙中國於2007年澳門威尼斯人^®開幕時，已率先前瞻性打造全澳最大規模的會展設施「金光會展」，為澳門的會展發展奠基國際競爭力。歷經多年發展，公司持續聚焦非博彩多元發展布局，助力推動會展業從探索階段走向高速增長，成功構建及豐富「一程多站」的整合發展模式。時至今日，旗下會展設施總面積已擴大至逾160萬平方呎，持續推動澳門會展業的國際化、專業化及規模化發展。

在中央人民政府及澳門特區政府的政策大力推動下，澳門會展業的發展空間得以不斷拓展，並逐步發展成為城市經濟適度多元的重要引擎之一。金沙中國作為澳門會展業的積極推動者，多年來充分發揮旗下世界級綜合旅遊休閒設施的優勢，為澳門提升舉辦大型會展活動的承載能力及競爭力，成功吸引眾多具全球影響力的高端會展項目落戶澳門。截至目前，公司在澳門累計舉辦近12,800項會展活動，當中涵蓋多個全球前沿行業領域，共吸引來自全球一共逾1,570萬人次參展，持續推動澳門成為大中華、亞洲、以至全球的重要會展旅遊目的地之一。

金沙中國深信，會展業具有強大的產業聯動效益，不僅帶動眾多關聯行業提質升級，更憑藉會展業的國際聯通性，匯聚大批國際專業人士及商務旅客，為澳門拓展更廣闊的國際客源市場。多年來，金沙中國透過引進及舉辦國際高端會展活動，不斷強化澳門對國際旅客的吸引力。單在2025年，公司旗下國際客入住晚數達380,000 住宿晚。

金沙中國有限公司行政總裁兼執行董事鄭君諾先生表示：「金沙中國多年來成功延展本澳會展業發展，將會展業深度融入綜合休閒度假村的營運及發展模式之中，並為澳門構建出具規模、高質量的會展基建，持續推動會展業成為澳門連接世界、提升國際競爭力及推動城市多元發展的重要名片及旅遊產品。自二零零七年至今，公司已累計吸引逾1,570萬人次參展；隨著本澳會展業發展成熟，澳門更成為具全球影響力的商務旅遊目的地之一，充分印證會展業的穩健發展為澳門多元產業注入強勁動能。未來，公司將持續全力配合澳門特區政府『旅遊+』的施政方針，確保非博彩產業的聯動效益，全面促進澳門經濟多元發展，進一步提升澳門全球競爭力及吸引力，助力鞏固澳門『世界旅遊休閒中心』的定位。」

金沙中國對澳門未來發展充滿信心，在提升業務發展的同時，公司將持續投放資源，全力對接澳門特區政府的整體發展策略，積極拓展高質量「旅遊+」非博彩項目，豐富澳門「盛事之都」內涵與吸引力，為澳門經濟適度多元發展注入長期動能。

關於金沙中國有限公司

金沙中國有限公司（香港聯交所：1928，「金沙中國」或「公司」）是一所於開曼群島註冊成立的有限公司及在香港聯合交易所有限公司上市的公司。金沙中國是澳門最大的綜合度假村經營商，於路氹金光大道上設有澳門威尼斯人^®、澳門百利宮、澳門巴黎人^®，以及澳門倫敦人^® 等物業項目，同時擁有及經營位於澳門半島的澳門金沙。公司旗下的各綜合度假村集合多樣化的娛樂消閒、商務設施及客運業務，包括大型會議及展覽場地、各式餐廳食肆、購物中心、於威尼斯人綜藝館、倫敦人綜藝館、威尼斯人劇場、巴黎人劇場、倫敦人劇場及金沙劇場舉行的世界級娛樂表演，以及來往港澳的金光飛航高速渡輪服務。公司在路氹金光大道的各物業發展項目，堅定並持續地為建設澳門成為世界旅遊休閒中心貢獻力量。金沙中國是全球度假村發展商拉斯維加斯金沙集團股份有限公司（紐約證券交易所：LVS）的附屬公司。

如欲索取更多相關資訊，請瀏覽網頁https://hk.sandschina.com/index.html。

傳媒查詢：

金沙中國有限公司 – 企業傳訊部
胡美寶
電話：+853 8118 2268
電郵：[email protected] 

鄭文軒
電話：+853 8118 2054
電郵：[email protected]

- 該研究證實，EGFR-TKI可誘導DTP細胞TROP2上調，為sac-TMT與EGFR-TKI聯合用藥提供機制依據。

- 公司正在開展兩項臨床試驗：sac-TMT聯合奧希替尼一線治療晚期EGFR突變NSCLC的III期注冊研究（已完成受試者入組，現處於隨訪階段）；以及該聯合方案用於可切除EGFR突變NSCLC新輔助治療的II期研究。

- sac-TMT已在中國獲批用於既往經TKI單藥治療後進展、或經TKI聯合含鉑化療後進展的晚期EGFR突變NSCLC，且在TKI耐藥人群中展現出顯著PFS與OS獲益。

成都2026年6月22日 /美通社/ -- 四川科倫博泰生物醫藥股份有限公司（以下簡稱「科倫博泰」或「公司」）宣布，旗下蘆康沙妥珠單抗（sac-TMT，研發代號：SKB264/MK-2870，商品名：佳泰萊^®）聯合奧希替尼一線治療晚期表皮生長因子受體(EGFR)突變非小細胞肺癌(NSCLC)的轉化研究成果已在線發表於國際學術期刊《Cancer Cell》。

該論文題為「Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer」，由中山大學腫瘤防治中心張力教授、方文峰教授團隊牽頭完成。研究顯示，經EGFR酪氨酸激酶抑制劑(TKI)治療後，殘存的藥物耐受持久性細胞(DTP)會出現滋養層細胞表面抗原2(TROP2)表達上調；臨床前模型證實，sac-TMT聯合奧希替尼可抑制DTP細胞形成並延緩腫瘤復發。上述研究結果為靶向TROP2抗體藥物偶聯物(ADC)與EGFR-TKI聯合用於延緩耐藥提供了轉化醫學證據，進一步凸顯sac-TMT作為EGFR-TKI核心聯合用藥搭檔的差異化價值。

基於上述研究成果與臨床開發計劃，公司正在推進一項III期注冊研究（試驗編號：NCT06670196），將sac-TMT聯合奧希替尼與奧希替尼單藥一線治療局部晚期或轉移性EGFR突變非鱗狀NSCLC進行對比。該研究旨在評估sac-TMT（4 mg/kg，每兩周給藥一次）聯合奧希替尼相較於奧希替尼單藥在此適應症下的療效與安全性。該研究已在中國完成全部受試者入組，目前進入隨訪與數據成熟階段。

除此之外，公司還在推進sac-TMT用於更早期EGFR突變NSCLC的臨床探索。一項II期臨床研究（試驗編號：NCT07329322）正在開展，評估sac-TMT聯合奧希替尼或sac-TMT單藥用於可切除EGFR突變NSCLC新輔助治療，進一步挖掘sac-TMT在圍手術期治療中的潛在價值。

本次研究成果刊發於《Cancer Cell》夯實了sac-TMT聯合EGFR-TKI一線治療EGFR突變NSCLC的科學理論基礎。依托sac-TMT在EGFR突變NSCLC領域已獲批的適應症及臨床開發計劃，公司將持續探索該聯合方案在前線治療、耐藥延緩、長期生存獲益等方面的應用潛力。科倫博泰將持續深耕EGFR突變NSCLC創新治療方案的研發，為患者提供更多治療選擇。

關於sac-TMT（佳泰萊^®）

作為公司的核心產品，sac-TMT是一款公司擁有自主知識產權的新型人源化TROP2 ADC，適應症覆蓋NSCLC、乳腺癌(BC)、胃癌(GC)、婦科腫瘤、泌尿生殖系統腫瘤等多種晚期實體瘤。sac-TMT采用獨特雙功能連接子開發而成：一端與抗TROP2單抗沙妥珠單抗不可逆結合，另一端可在溶酶體內發生pH依賴性裂解，釋放貝洛替康衍生物拓撲異構酶I抑制劑載荷，從而最大限度地將毒性載荷遞送至腫瘤細胞，藥物抗體比(DAR)達7.4。sac-TMT通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面TROP2，經腫瘤細胞內吞後，在細胞內釋放毒性載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞周期阻滯與凋亡。此外，KL610023會被釋放至腫瘤微環境。由於KL610023具備細胞膜穿透性，可產生旁觀者效應，殺傷周邊腫瘤細胞。

2022年5月，公司授予默沙東（美國新澤西州羅威市默克公司的商號）在大中華區（包括中國大陸、香港、澳門及台灣）以外的全球所有地區開發、使用、制造及商業化sac-TMT的獨家權利。

截至目前，sac-TMT在中國已獲批四項適應症並實現商業化上市：1)既往接受至少兩種系統治療（其中至少一種治療針對晚期/轉移性階段）的不可切除局部晚期或轉移性三陰性乳腺癌(TNBC)；2)經EGFR-TKI聯合含鉑化療後進展的EGFR突變陽性局部晚期或轉移性非鱗狀NSCLC；3)經EGFR-TKI單藥治療後進展的EGFR突變陽性局部晚期或轉移性非鱗狀NSCLC；4)既往接受內分泌治療且晚期階段至少接受過一線化療的不可切除或轉移性激素受體陽性(HR+)、人表皮生長因子受體2陰性（HER2-，免疫組織化學(IHC) 0、IHC 1+或IHC 2+/原位雜交(ISH)-) BC。上述前兩項適應症已納入中國國家醫保藥品目錄(NRDL)，有望為更多BC和NSCLC患者帶來具有臨床意義的生存獲益。同時，sac-TMT已獲中國國家藥品監督管理局(NMPA)授予六項突破性療法認定(BTD)。

sac-TMT是全球首個在肺癌適應症領域獲批上市的TROP2 ADC藥物。sac-TMT的新增適應症上市申請已獲NMPA受理，用於聯合帕博利珠單抗（可瑞達^®[1]）一線治療腫瘤細胞程序性死亡配體1(PD-L1)腫瘤細胞陽性比例評分(TPS)≥1%、EGFR陰性/間變性淋巴瘤激酶(ALK)陰性的局部晚期或轉移性NSCLC，並進入優先審評審批通道。截至當前，科倫博泰已在中國啟動9項注冊臨床研究。默沙東正在全球開展17項III期臨床研究，評估sac-TMT單藥或聯合帕博利珠單抗或其他抗癌藥物用於多種類型癌症的治療。這些研究均由默沙東發起並牽頭。

關於科倫博泰

科倫博泰（股票代碼：6990.HK）是科倫藥業旗下控股子公司，專注創新生物藥和小分子藥物的研發、生產、商業化及全球合作。公司聚焦實體瘤、自身免疫疾病、代謝性疾病等重大疾病領域，搭建全球化藥物研發與產業化平台，滿足國內外未被滿足的臨床用藥需求，致力於成為全球領先的創新藥企。目前，公司擁有30余個在研核心創新藥項目，其中4個項目共8個適應症已獲批上市，1個項目處於新藥上市申請(NDA)階段，十余個項目進入臨床研究階段。公司成功構建了全球領先的專有ADC與新型DC技術平台OptiDC™，現有2款ADC產品共5個適應症已獲批上市，多款ADC及新型DC產品處於臨床或臨床前研究階段。有關更多詳情，請訪問官網：https://en.kelun-biotech.com/

上海2026年6月22日 /美通社/ -- 科濟藥業（股票代碼：2171.HK），一家專注於開發創新CAR-T細胞療法的生物制藥公司宣布，今日已收到國家藥品監督管理局（NMPA）通知，批准其自主研發的Claudin18.2自體人源化CAR-T細胞治療產品——愷力美^®（舒瑞基奧侖賽注射液）新藥上市申請，用於治療Claudin18.2陽性、人表皮生長因子受體2（HER2）陰性，至少二線治療失敗的晚期胃/食管胃結合部腺癌。愷力美^®是全球首款獲批用於實體瘤治療的CAR-T細胞治療產品。

胃癌在全世界范圍內是疾病負擔較重的惡性腫瘤之一，發病率和死亡率均位居全球腫瘤的第5位，每年新發病例高達約97萬例，死亡病例約66萬例^[1]。其中，超過70%的新發和死亡病例來自亞洲地區^[2]，中國胃癌患者占全球患病人數約47%^[3]。根據中國國家癌症中心統計數據，2022年中國胃癌新發病例約36萬人，死亡病例高達26萬人，分別位居中國癌症發病和死亡人數的第5位和第3位^[4]。盡管外科技術和綜合治療手段在不斷發展，但胃癌起病隱匿，目前我國早期胃癌診斷比例仍不足20%，晚期胃癌5年生存率僅10%左右^[5]。胃癌存在發病率高、早診率低、異質性高、死亡率高等特點，目前傳統化療藥物已進入瓶頸期，靶向藥物選擇有限，免疫治療的獲益人群比例及獲益程度仍亟待提高。因此，不可切除或轉移性胃癌患者仍存在巨大的未被滿足的醫療需求，迫切需要推動更多精準治療和新型抗腫瘤藥物的發現與探索。

Claudin18.2是一種高選擇性標記蛋白，在正常健康組織中表達十分有限，僅在已分化的胃粘膜上皮細胞中表達，而在胃癌等多種惡性腫瘤中呈現高表達。愷力美^®是一款靶向Claudin18.2的自體CAR-T細胞產品，它是經基因修飾以表達由人源化Claudin18.2特異性單鏈單抗（hu8E5-2I）、CD8α鉸鏈區、CD28跨膜區、CD28胞內信號域（CD28 ICD）及CD3ζ胞內信號區組成的CAR構建體。盡本公司所知，我們在全球范圍內率先成功識別、驗證並報告實體瘤相關抗原Claudin18.2作為CAR-T細胞療法的有效靶點。為了進一步解決CAR-T細胞療法治療實體瘤腫瘤微環境的挑戰，本公司針對愷力美^®自主研發了一種受專利保護的創新性清淋預處理方案，特點是在傳統方案（環磷酰胺和氟達拉濱）基礎上加入低劑量的白蛋白結合型紫杉醇以增強CAR-T細胞的滲透和抗腫瘤效果。本公司圍繞愷力美^®進行全球專利佈局，覆蓋靶點、適應症、給藥劑量和預處理方案等。

愷力美^®的臨床療效得到了國際頂級醫學期刊的權威認可，其確證性隨機對照研究結果發表於《柳葉刀》（The Lancet）^[6]。臨床數據顯示，對於治療選擇極其有限、預後極差的晚期末線胃/食管胃結合部癌患者，愷力美^®展現出較現有治療顯著的療效獲益和良好的安全性，為晚期胃癌患者帶來了全新的治療選擇。這一重大突破不僅確立了實體瘤CAR-T治療的新標准，更為後續推進早線治療、聯合治療方案探索，以及拓展應用於胰腺癌、膽道癌等其他Claudin18.2陽性實體瘤奠定了堅實的科學基礎。

愷力美^®的研發和獲批上市，不僅是企業研發實力的體現，更是國家創新藥全鏈條政策生態與監管改革成效的集中印證。得益於藥品審評審批制度改革持續深化以及創新藥全鏈條支持政策落地見效，全球首個針對實體瘤的CAR-T細胞治療產品得以在中國率先誕生。在這一過程中，監管部門的科學指引與關鍵支撐貫穿始終。面對迫切的臨床需求和技術挑戰，國家藥監局藥品審評中心及長三角分中心專家團隊堅持科學原則，在關鍵臨床試驗啟動前即與公司開展多輪前瞻性溝通，對試驗設計等關鍵環節給予專業指導；臨床試驗期間持續在藥學、非臨床等方面提供專業支持。正是「研審聯動、全程賦能」的監管模式保障了項目高效推進，產出經得起國際同行評議的高質量臨床數據。憑借其突出的臨床價值與優異的試驗數據，產品也由此先後被納入突破性治療藥物品種並獲得優先審評資格。與此同時，上海市藥品監督管理局始終以主動擁抱創新的服務理念，為公司提供了精準高效的技術指導，積極搭建聯動橋梁，並在生產許可、抽樣檢查與GMP符合性核查等關鍵環節全力推動，有力保障了上市進程。這些舉措充分彰顯了藥監部門支持真創新、服務真價值的堅定態度與專業擔當，也體現了中國特色科學監管體系對本土原研藥走向世界的強大支撐。

北京大學腫瘤醫院沈琳教授團隊牽頭開展了舒瑞基奧侖賽注射液的臨床研究。沈琳教授表示：「對於經歷過多線治療失敗的晚期胃/食管胃結合部腺癌患者而言，既往治療手段極其匱乏，預後極差。舒瑞基奧侖賽注射液的獲批，為我們提供了全新的、有效的治療武器。該產品為此類患者帶來了具有臨床意義的顯著獲益，其卓越療效是現有治療手段難以企及的。更為重要的是，作為一款CAR-T產品，舒瑞基奧侖賽讓患者有機會擺脫頻繁往返醫院接受治療的束縛，實現從『延長生存』到『改善生活』的跨越。作為全球首個成功上市的實體瘤CAR-T療法，舒瑞基奧侖賽不僅填補了晚期胃癌後線治療的空白，更開創了實體瘤細胞治療的全新時代。這一突破為後續推進前線治療、聯合治療策略等奠定了關鍵基礎，有望重塑胃癌乃至消化道腫瘤的治療格局。我們相信，隨著臨床應用的推廣，這一創新療法將為廣大胃癌患者點亮生命的新希望。」

科濟藥業創始人、董事會主席、首席執行官、首席科學官李宗海博士表示：「愷力美^®的獲批上市，是CAR-T細胞治療從血液瘤邁向實體瘤的重要裡程碑事件，這離不開參與臨床試驗的患者及其家屬、研究者團隊、合作伙伴、監管機構及相關部門的信任和支持。我們將全力以赴推進愷力美^®的臨床應用與市場准入，確保這一創新療法能夠及時、廣泛地惠及中國患者。同時，我們也將努力把該產品擴展到更多的國家和地區，以滿足更多的醫療需求。此外，我們也在探索晚期胃癌一線序貫治療及術後輔助治療等，以期幫助更多患者獲得更深遠的治療獲益，甚至治愈的可能。」

關於愷力美^®

愷力美^®是一款全球同類首創靶向Claudin18.2蛋白的自體CAR-T細胞治療產品，用於治療Claudin18.2陽性實體瘤。愷力美^®於2026年6月獲國家藥品監督管理局批准上市，用於治療Claudin18.2陽性、人表皮生長因子受體2（HER2）陰性，至少二線治療失敗的晚期胃/食管胃結合部腺癌，成為全球首個批准上市實體瘤CAR-T細胞治療品種。

本公司正積極擴展愷力美^®在癌症早期治療和圍術期治療中的應用佈局：包括一項正在中國開展的針對胰腺癌輔助治療的I期臨床試驗（NCT05911217）、一項用於根治術後的胃/胃食管結合部腺癌患者輔助治療後的鞏固治療的研究者發起的臨床試驗（NCT06857786）及一項用於胃/胃食管結合部腺癌一線治療後的序貫治療的研究者發起的臨床試驗（NCT07179484）。

關於科濟藥業

科濟藥業（股票代碼：2171.HK）是一家生物制藥公司，專注於開發創新CAR-T細胞療法，以滿足未滿足的臨床需求，包括但不限於血液惡性腫瘤、實體瘤及自身免疫性疾病。公司形成了從靶點發現、臨床前研究、產品臨床開發到商業規模生產的CAR-T細胞研究與開發的端到端能力。公司通過自主研發新技術以及擁有全球權益的產品管線，以解決現有CAR-T細胞療法的挑戰，比如提高安全性，提高實體瘤治療的療效和降低治療成本等。科濟藥業的使命是成為全球生物制藥領域的領導者，為全球癌症及其他疾病的患者提供創新和差異化的細胞療法，使癌症及其他疾病可治愈。

前瞻性聲明

本新聞稿中所有不屬於歷史事實或與當前事實或當前條件無關的陳述都是前瞻性陳述。此類前瞻性聲明表達了本集團截至本新聞稿發布之日對未來事件的當前觀點、預測、信念和預期。此類前瞻性聲明是基於本集團無法控制的一些假設和因素。因此，它們受到重大風險和不確定性的影響，實際事件或結果可能與這些前瞻性聲明有重大差異，本新聞稿中討論的前瞻性事件可能不會發生。這些風險和不確定性包括但不限於我們最近的年度報告和中期報告以及在我們公司網站https://www.carsgen.com 上發布的其他公告和報告中「主要風險和不確定性」標題下的詳細內容。對於本新聞稿中的任何預測、目標、估計或預測的實現或合理性，我們不作任何陳述或保證，也不應依賴這些預測。

聯繫科濟藥業
更多信息，請訪問公司網站：https://www.carsgen.com/
公共關系：[email protected] 
投資者關系：[email protected]

— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.

— The Company is conducting a Phase III registrational study of sac-TMT plus osimertinib as first-line treatment for advanced EGFR-mutant NSCLC (enrollment completed; follow‑up phase) and a Phase II study of the same combination as neoadjuvant treatment for EGFR-mutant resectable NSCLC.

— Sac-TMT has been approved in China for advanced EGFR-mutant NSCLC following progression on TKI therapy or TKI therapy and platinum-based chemotherapy, and has demonstrated significant PFS and OS benefits in TKI-resistant settings.

CHENGDU, China, June 22, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that translational research results on its sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱^®) in combination with osimertinib as first-line treatment for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) have been published online in Cancer Cell, an international academic journal.

The paper, titled "Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer," was led by Professor Li Zhang and Professor Wenfeng Fang from the Sun Yat-sen University Cancer Center. The study shows that trophoblast cell-surface antigen 2 (TROP2) expression is upregulated in residual drug-tolerant persister (DTP) cells after EGFR tyrosine kinase inhibitor (TKI) treatment; in preclinical models, sac-TMT combined with osimertinib inhibited DTP cell formation and delayed tumor recurrence. These findings provide translational medicine evidence for the combination of TROP2-directed antibody drug conjugate (ADC) and EGFR‑TKI in delaying drug resistance, and further underscore the differentiated value of sac-TMT as a key combination partner for EGFR-TKIs.

Building on the above research and clinical development plans, the Company is advancing a Phase III registrational study (NCT06670196) of sac-TMT in combination with osimertinib versus osimertinib monotherapy as first-line treatment for locally advanced or metastatic EGFR-mutant non-squamous NSCLC. The study is designed to evaluate the efficacy and safety of sac-TMT (4 mg/kg, Q2W) plus osimertinib compared with osimertinib monotherapy in this indication. Patient enrollment in China has been completed, and the study is currently in the follow-up and data maturity phase.

In addition, the Company is advancing clinical exploration of sac-TMT for earlier-stage EGFR-mutant NSCLC. A Phase II study (NCT07329322) is ongoing to evaluate sac-TMT in combination with osimertinib or as monotherapy in the neoadjuvant setting for EGFR-mutant resectable NSCLC, further exploring the potential value of sac-TMT in perioperative treatment.

This publication in Cancer Cell reinforces the scientific foundation for combining sac-TMT with EGFR-TKIs as first-line treatment for EGFR-mutant NSCLC. The Company will continue to explore the potential of this combination regimen in earlier-line treatment, resistance delay, and long-term benefit, building on the approved indications and clinical development plan of sac-TMT in EGFR-mutant NSCLC. Kelun-Biotech remains committed to driving innovation in treatment paradigms for EGFR-mutant NSCLC and expanding therapeutic options for patients.

About sac-TMT(佳泰莱^®)

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic triple‑negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy; 3) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (Immunohistochemistry (IHC) 0, IHC 1+ or IHC 2+/In Situ Hybridization (ISH)-) BC who have received prior endocrine therapy and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China's National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the National Medical Products Administration (NMPA).

Sac-TMT is the world's first TROP2 ADC drug approved for marketing in lung cancer. A new indication application for sac-TMT in combination with pembrolizumab (KEYTRUDA^®[1]) as first‑line treatment for locally advanced or metastatic NSCLC who have programmed death ligand 1 (PD-L1) tumor proportion score (TPS)≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD is evaluating 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.  

• Important addition to China-related risk management tools offered by HKEX
• Supporting growth of Hong Kong's RMB product ecosystem

HONG KONG, June 18, 2026 /PRNewswire/ -- Hong Kong Exchanges and Clearing Limited (HKEX) welcomes the announcement today (Thursday) by the Securities and Futures Commission (SFC) on the target launch of 5-year China Government Bond (CGB) Futures in Hong Kong on 3 August 2026.

HKEX Chairman, Carlson Tong, said: "The debut of CGB Futures in Hong Kong with the 5-year tenor as the first contract marks an important milestone in the development of Hong Kong's Fixed-Income and Currencies (FIC) ecosystem. We thank the regulators in Hong Kong and the Chinese Mainland for their staunch support, and we look forward to working closely with our partners and stakeholders to ensure the successful rollout of this new risk-management tool and further enhance two-way capital flows between China and the world."

HKEX Chief Executive Officer, Bonnie Y Chan, said: "The launch of CGB Futures is another exciting step that enriches HKEX's China-related product suite and FIC offering. Complementing Bond Connect and following the success of Swap Connect, these unique CGB Futures will provide investors of Chinese bonds with an efficient risk management tool, supporting the growth of Hong Kong's RMB product ecosystem and cementing Hong Kong's role as the world's leading offshore RMB hub. We will continue to work with all stakeholders in building Hong Kong's FIC ecosystem and enriching global investors' options."

More details about the CGB Futures will be announced in due course.

The launch of the contract, part of HKEX's RMB and Mainland-related suite of products that includes Stock Connect, Bond Connect, Swap Connect and MSCI China A50 Connect Index Futures, will help regional and global investors interested in accessing the Chinese Mainland to more effectively manage their interest rate risks. This will support greater international participation in the domestic equities and fixed-income markets and further broaden investment and risk management opportunities in Hong Kong's markets.

The launch of Bond Connect in 2017, part of HKEX's unique mutual market access programme with the Chinese Mainland, was an important development in driving international participation in the Mainland's bond market, whilst Swap Connect, which launched in 2023, allows international investors to tap the onshore RMB interest rate swap market. International investors' onshore bonds holdings in the China Interbank Bond Market have grown steadily from RMB0.8 trillion in June 2017 to around RMB3.2 trillion at the end of May 2026.

About HKEX

Hong Kong Exchanges and Clearing Limited (HKEX) is a publicly-traded company (HKEX Stock Code:388) and one of the world's leading global exchange groups, offering a range of equity, derivative, commodity, fixed income and other financial markets, products and services, including the London Metal Exchange.

As a superconnector and gateway between East and West, HKEX facilitates the two-way flow of capital, ideas and dialogue between China and the rest of the world, through its pioneering Connect schemes, increasingly diversified product ecosystem and its deep, liquid and international markets.

HKEX is a purpose-led organisation which, across its business and through the work of HKEX Foundation, seeks to connect, promote and progress its markets and the communities it supports for the prosperity of all.

www.hkexgroup.com 

KNOWLEDGE ATLAS (02513.HK) once ballooned 42.3% this morning (22nd), hitting an intraday high of HKD2,980 and marking a seven-session winning streak. The stock was last at HKD2,562, up 22.35%, with turnover of 2.4277 million shares, involving HKD6.084 billion. Market cap breached HKD1 trillion.

In response to an online question about when China’s large language models (LLMs) could reach the level of Anthropic’s Fable, and noting that KNOWLEDGE ATLAS’s GLM-5.2 has narrowed the gap, Tesla, Inc. (TSLA.US) CEO Elon Musk replied that it could happen in 1Q27.

Musk’s remarks prompted a response from KNOWLEDGE ATLAS Founder cum CEO Tang Jie, who said the gap may not take that long to close.

AI industry insiders generally view Musk’s forecast as relatively conservative, estimating that the time gap between Chinese and US models could be shorter than seven months.
~

AASTOCKS Financial News
Website: www.aastocks.com

JD-SW (09618.HK) announced that the number of users placing orders during JD 618 marked a new high from 8:00 pm on May 30 to 11:59 pm on June 18, with brisk growth in multi-category service consumption.

During this year’s 618 period, the GMV of JD housekeeping daily cleaning services mushroomed by more than 200% YoY, while home appliance cleaning transaction value shot up by more than 300% YoY.

The number of transactions for home appliances and home furnishing products bundled with integrated delivery and installation services rallied by more than 120%.

Meanwhile, the number of major new product launches by brands leapfrogged by more than 5x YoY. The number of small and medium-sized new merchants participating in 618 rose by over 62%, with more than 3,000 first-time participating merchants achieving transaction value exceeding RMB1 million.

Home appliance brands including MIDEA GROUP (00300.HK), HAIER SMARTHOME (06690.HK), HISENSE HA (00921.HK), TCL ELECTRONICS (01070.HK), GREE APPLIANCES (000651.SZ) and XIAOMI-W (01810.HK) each recorded a GMV of over RMB1 billion.

Among smart digital brands, DJI, Insta360 and CREALITY (03388.HK) posted nearly 100% YoY growth in GMV. High-end smartphones and premium lightweight laptops represented by Apple Inc. (AAPL.US), LENOVO GROUP (00992.HK), Huawei and ASUS charted YoY GMV spike of 300% and 100%, respectively.

In Hong Kong, JD MALL’s Wan Chai store attracted over 10,000 visitors in its first hour of opening, setting a single-day, single-store sales record among similar electrical appliance retail malls in Hong Kong.

During the 618 period, JD Kai Bo Food Supermarket’s Wan Chai branch also opened, bringing the total number of stores in Hong Kong to over 100, with sales hiking by more than 52% YoY.
~

AASTOCKS Financial News
Website: www.aastocks.com

SAN FRANCISCO and SUZHOU, China, June 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is China's first self-developed anti-GPRC5D/BCMA/CD3 tri-specific antibody to enter the pivotal registrational Phase III clinical trial, aiming to bring a promising next-generation immunotherapy option for Chinese R/R MM patients.

TriadicMM-1 (NCT07623798) is a multicenter, randomized, controlled, open-label Phase 3 clinical trial designed to evaluate the efficacy and safety of IBI3003 versus investigator's choice of regimen (pomalidomide, bortezomib and dexamethasone [PVd] or daratumumab, pomalidomide and dexamethasone [DPd]). The primary endpoint of the study is progression-free survival (PFS) assessed by the Independent Review Committee (IRC).

Clinical data presented at the American Society of Hematology (ASH) Annual Meeting on December 7, 2025 [Link], demonstrated a tolerable safety profile and promising efficacy signals for IBI3003 in patients who had failed ≥2 prior lines of myeloma therapy:

• Thirty-nine patients with R/R MM who had previously received at least a PI, an IMiD, and an anti-CD38 monoclonal antibody were treated with IBI3003 at dose levels ranging from 0.1 μg/kg to 800 μg/kg and underwent at least one tumor assessment after baseline. As of the data cutoff date of November 7, 2025, the median follow-up duration was 3.25 months (range: 0.4–7.4), and the median treatment duration was 12.14 weeks (range: 1.0–33.0).
• Among patients treated at doses ≥120 μg/kg (n=24), the overall response rate (ORR) was 83.3%, including 4 stringent complete responses (sCR), 7 very good partial responses (VGPR), and 9 partial responses (PR). In this cohort, the ORR was 80% among 10 patients with extramedullary disease (EMD) and 77.8% among 9 patients previously treated with BCMA- and/or GPRC5D-directed therapies. Among patients who achieved complete response or better, the minimal residual disease (MRD) negativity rate was 100% (n=4), as assessed by validated next-generation sequencing, with a threshold of 10^-5, performed at a central laboratory.
• All cases of cytokine release syndrome (CRS) were Grade 1-2, with only 2 cases of Grade 1-2 immune effector cell-associated neurotoxicity syndrome (ICANS) reported. Most treatment-emergent adverse events (TEAEs) related to GPRC5D targeting, including those affecting the oral cavity, skin, and nails, were Grade 1–2, with two patients experiencing Grade 3 rash.
• Relevant dose optimization data (including RP2D selection) from this Phase 1/2 study will be presented at future academic conferences.
• In addition, IBI3003 has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) earlier this year. This designation applies to the treatment of R/R MM in patients who have received four or more lines of previous anti-myeloma therapies, that include at least a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody. The Phase I/II clinical trial in the United States is currently underway.

Professor Peng Liu from Zhongshan Hospital Affiliated to Fudan University, the Principal Investigator of the TriadicMM-1 Study, stated: "We are delighted that the first patient has been enrolled in TriadicMM-1 at our hospital. This is the first domestic pivotal Phase 3 clinical trial of a tri-specific antibody with independent intellectual property rights for the treatment of R/R/MM in China. Furthermore, IBI3003 is also the second tri-specific antibody globally to have advanced into pivotal Phase III clinical development in the R/R MM setting. Although multiple myeloma has multiple treatment options, the disease still recurs most frequently and is incurable. With each recurrence, symptoms reappear, quality of life declines, and both the likelihood and duration of treatment response typically decrease. Therefore, there remains a significant and urgent unmet medical need for novel therapeutic agents targeting alternative mechanisms of action to better control the disease, achieve deeper and more durable responses, and improve long-term outcomes including maintaining health-related quality of life. We highly anticipate that the Phase III study TriadicMM-1 will validate the potential of IBI3003 and establish IBI3003 as a new standard of care for 2-5 line R/R MM."

Dr. Hui Zhou, Chief R&D Officer (Oncology Pipeline) of Innovent Biologics, stated: "The successful completion of the first patient's first dose in the Chinese pivotal Phase III study TriadicMM-1 of IBI3003 is an important milestone for Innovent in advancing its first tri-specific antibody program into the registrational stage. IBI3003 is built on Innovent's proprietary Sanbody^® platform. The promising efficacy data and manageable safety profile observed in preclinical and clinical studies are expected to bring a promising next-generation immunotherapy option for patients with multiple myeloma. Looking ahead, Innovent will deepen its dual innovation in ADC and immunotherapy, and is committed to delivering cutting-edge therapies to patients worldwide."

About Multiple Myeloma

Multiple Myeloma is a malignant hematological malignancy originating from plasma cells in the bone marrow, ranking as the second most common blood cancer globally. Abnormal, clonal expansion of these malignant plasma cells crowding the bone marrow disrupts normal hematopoiesis and secretes abnormal monoclonal immunoglobulins (M protein). This process leads to a series of severe clinical complications, classically characterized by bone destruction, anemia, renal impairment, and hypercalcemia.

Driven by an aging global population, the incidence of multiple myeloma is continuously rising. Although the introduction of innovative therapies—such as proteasome inhibitors, immunomodulatory drugs, and targeted agents—has significantly improved patient prognosis over the past decades, multiple myeloma remains largely incurable. The vast majority of patients who initially achieve remission will inevitably experience a relentless cycle of relapse and drug resistance.

For patients with relapsed/refractory multiple myeloma who have already progressed through 1-4 lines of therapy, subsequent treatment options become severely limited. With each successive line of therapy, the duration of remission shortens, and the prognosis worsens drastically. Consequently, there is a critical and unmet medical need for novel therapeutic regimens with superior efficacy, manageable safety profiles, and distinct mechanisms of action to overcome resistance, prolong overall survival, and preserve patient quality of life.

About IBI3003

IBI3003, constructed on Innovent's proprietary Sanbody^® platform, is a novel trispecific antibody targeting G protein–coupled receptor, family C, group 5, member D (GPRC5D), B-cell maturation antigen (BCMA) and CD3. This molecular design aims to overcome single tumor antigen escape. Its antitumor activity in preclinical mouse models is superior to that of marketed bispecific antibody benchmarks, and it exhibits particularly potent tumor killing efficacy in in vitro cell models with low expression of BCMA and GPRC5D.

Currently, a Phase I/II clinical trial of IBI3003 is underway in China, Australia and U.S. (NCT06083207) to explore the safety, tolerability and efficacy of IBI3003 in subjects with R/R MM. In China, the program has advanced into pivotal registration stage with TriadicMM‑1 (NCT07623798), a randomized, controlled, open‑label Phase III study comparing IBI3003 to investigator's choice of regimens (DPd or PVd). The primary endpoint is progression‑free survival (PFS) assessed by an independent review committee (IRC).

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 1 asset in NMPA NDA review, 4 assets in Phase 3 or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.

Disclaimer: Innovent does not recommend any off-label usage.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

Reference：

1. Rajkumar SV, et al. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022 Aug;97(8):1086-1107.
2. Kumar SK, et al. International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan;26(1):149-57.
3. Zhuge L, et al. Global, regional and national epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021. Front Public Health. 2025 Jan 27;13:1527198.